PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsBecaplermin
Regranex(becaplermin)
Regranex (becaplermin) is a protein pharmaceutical. Becaplermin was first approved as Regranex on 1997-12-16. It is used to treat diabetic neuropathies in the USA. It has been approved in Europe to treat skin ulcer and wound healing.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
biological phenomenaD001686
Trade Name
FDA
EMA
Regranex
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Becaplermin
Tradename
Proper name
Company
Number
Date
Products
RegranexbecaplerminSmith+NephewN-103691 RX1997-12-16
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
regranexBiologic Licensing Application2023-12-11
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic neuropathiesEFO_1000783D003929—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AD: Other agents for local oral treatment in atc
— A01AD08: Becaplermin
D: Dermatologicals
— D03: Preparations for treatment of wounds and ulcers
— D03A: Cicatrizants
— D03AX: Other cicatrizants in atc
— D03AX06: Becaplermin
HCPCS
Code
Description
S0157
Becaplermin gel 0.01%, 0.5 gm
Clinical
Clinical Trials
43 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic footD017719EFO_1001459———1—23
Diabetic neuropathiesD003929EFO_1000783———1—12
Foot ulcerD016523————1—12
UlcerD014456MPATH_579———1——1
Skin ulcerD012883—L98.4——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
BurnsD002056—T30.0—1———1
Electric burnsD002058———1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E13————22
NeoplasmsD009369—C80————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBecaplermin
INNbecaplermin
Description
Platelet-derived growth factor, B chain precursor (PDGF B-chain) (Platelet-derived growth factor beta polypeptide)
Classification
Protein
Drug classgrowth factors: platelet derived growth factors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201556
ChEBI ID—
PubChem CID—
DrugBankDB00102
UNII ID1B56C968OA (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Becaplermin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,674 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,119 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use